January 2006 Cover
|
 |
The Food and Drug Administration has approved a new formulation of Kaletra. Kaletra (lopinavir/ritonavir) is now available as a film coated tablet (200mg/50mg) that provides advantages over the currently marketed capsule formulation for HIV-1 infected patients. Specifically,
the tablet formulation:
· does not require refrigeration,
· can be administered without regard to meals
· does not require dose adjustments for concomitant use with certain NNRTIs and PIs in treatment-naive patients
· has a decreased pill burden compared to the capsule formulation (two tablets twice daily or four tablets once daily in treatment-naive patients only versus three capsules twice daily or six capsules once daily in treatment-naive patients only).
Editor's Note: from www.thebodypro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
